Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001

scientific article

Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001 is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S12185-009-0345-Y
P932PMC publication ID4378576
P698PubMed publication ID19484334

P50authorJorge Eduardo CortesQ60320900
Hagop KantarjianQ60394812
Srdan VerstovsekQ64026418
Josef T PrchalQ88569926
Carlos B Bueso-RamosQ90223571
Roberto H NussenzveigQ90764300
Taghi ManshouriQ91467065
Matjaž SeverQ114304868
Pat AultQ114428008
P2093author name stringAlfonso Quintás-Cardama
P2860cites workA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraQ28241887
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cellsQ28277030
JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factorQ28637652
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisQ29614337
A gain-of-function mutation of JAK2 in myeloproliferative disordersQ29618851
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersQ29618853
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosomeQ33336718
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.Q33371084
Molecular basis for polycythemiaQ33544141
Identification of an acquired JAK2 mutation in polycythemia veraQ33947635
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disordersQ35771147
Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylateQ36113013
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemiaQ37405046
Imatinib effect on growth and signal transduction in polycythemia veraQ40127047
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.Q43031345
Polycythemia vera responds to imatinib mesylateQ44364237
Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitroQ44451881
Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia veraQ44452184
Imatinib mesylate in polycythemia veraQ44834834
Phase II open label trial of imatinib in polycythemia rubra veraQ46246672
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersQ46513376
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alphaQ46849974
Identification of c-Kit gene mutations in patients with polycythemia veraQ46930055
Letter: Bone-marrow responses in polycythemia veraQ47871256
Polycythemia vera is not initiated by JAK2V617F mutation.Q54564679
JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?Q58455742
P433issue1
P921main subjectimatinibQ177094
polycythemia veraQ948318
P304page(s)58-63
P577publication date2009-05-30
P1433published inInternational Journal of HematologyQ6051416
P1476titleImatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001
P478volume90

Reverse relations

cites work (P2860)
Q43731510Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study
Q38130749Emerging drugs for polycythemia vera
Q37833893Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Q38081267Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance
Q37869152New JAK2 inhibitors for myeloproliferative neoplasms
Q38774457Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?

Search more.